People: Thoratec Corp (THOR.O)
THOR.O on Nasdaq
32.60USD
17 May 2013
32.60USD
17 May 2013
Price Change (% chg)
$-0.63 (-1.90%)
$-0.63 (-1.90%)
Prev Close
$33.23
$33.23
Open
$33.37
$33.37
Day's High
$33.40
$33.40
Day's Low
$32.40
$32.40
Volume
1,187,489
1,187,489
Avg. Vol
634,810
634,810
52-wk High
$39.86
$39.86
52-wk Low
$29.39
$29.39
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Neil Dimick |
63 | 2007 | Independent Chairman of the Board |
Gerhard Burbach |
51 | 2006 | President, Chief Executive Officer, Director |
Taylor Harris |
37 | 2012 | Chief Financial Officer, Vice President |
David Lehman |
52 | 2007 | Senior Vice President, General Counsel, Secretary |
J. Daniel Cole |
66 | 1997 | Independent Director |
Steven Collis |
51 | 2008 | Independent Director |
Elisha Finney |
51 | 2007 | Independent Director |
D. Keith Grossman |
52 | 2006 | Independent Director |
William Hawkins |
59 | 2012 | Independent Director |
Paul LaViolette |
2009 | Independent Director | |
Daniel Mulvena |
64 | 1997 | Independent Director |
Biographies
| Name | Description |
|---|---|
Neil Dimick |
Mr. Neil F. Dimick, CPA is Independent Chairman of the Board of Thoratec Corporation. In May 2007, Mr. Dimick became Chairman of the Board. Mr. Dimick was Executive Vice President and Chief Financial Officer of AmerisourceBergen Corporation, a pharmaceutical services company, from August 2001 to May 2002, and served as Senior Executive Vice President and Chief Financial Officer and a director of Bergen Brunswig Corporation, a predecessor to AmerisourceBergen, and was a member of that board's finance, investment and retirement committees for more than five years prior to its merger with AmeriSource Health in 2001. Mr. Dimick also spent eighteen years with the audit firm Deloitte & Touche LLP, where he was an audit partner and national director of the firm's real estate division. Mr. Dimick currently serves as a member of the board of directors of Alliance Imaging, Inc., Mylan Laboratories, Inc., Resources Connection, Inc. and WebMD Corporation and has additionally in the past five years served as a member of the board of directors of Emdeon Corporation and HLTH Corporation. |
Gerhard Burbach |
Mr. Gerhard F. Burbach is President, Chief Executive Officer, Director of Thoratec Corp. From April 2005 to January 2006, Mr. Burbach served as President and Chief Executive Officer of Digirad Corporation, a provider of solid-state imaging products and services to cardiologist offices, hospitals and imaging centers. Before that he served for two years as president and chief executive officer of Bacchus Vascular Inc., a developer of interventional cardiovascular devices. Previously, he served for three years as chief executive officer of Philips Nuclear Medicine, a division of Philips Medical Systems specializing in nuclear medicine imaging systems. Until its acquisition by Philips Medical Systems, he spent four years at ADAC Laboratories, a provider of nuclear medicine imaging equipment and radiation therapy planning systems, where he became president and general manager of the nuclear medicine division. Mr. Burbach also spent six years with the consulting firm of McKinsey & Company, Inc., where he was most recently a senior engagement manager in the firm's healthcare practice. |
Taylor Harris |
Mr. Taylor C. Harris is Chief Financial Officer, Vice President of Thoratec Corp. Mr. Harris joined Thoratec in 2010 as Senior Director of Investor Relations and Business Development. Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm’s Healthcare Investment Banking and Equity Research departments. In these roles, Mr. Harris covered the medical device sector as an investment research analyst and advised healthcare companies on a broad range of strategic and capital markets transactions. Mr. Harris holds a B.A. in Physics and Economics from the University of North Carolina at Chapel Hill. |
David Lehman |
Mr. David A. Lehman is Senior Vice President, General Counsel, Secretary of Thoratec corp. He joined the company as Vice President and General Counsel in May 2003. Mr. Lehman was appointed as Secretary in December 2004 and became Senior Vice President in February 2007. Prior to joining the company, Mr. Lehman served as Vice President and General Counsel of Brigade Corporation, a provider of business process outsourcing services, from June 2000 to May 2003. From November 1997 to June 2000, Mr. Lehman was Assistant General Counsel at Bio-Rad Laboratories, Inc., a diagnostic and life science products company. Prior to November 1997, Mr. Lehman was in the legal department of Mitsubishi International Corporation, in New York and Tokyo, for more than seven years. Mr. Lehman started his career as an associate attorney at the law firm of Hall, Dickler, Kent, Friedman and Wood. Mr. Lehman has a Bachelors of Arts in political science from the University of California, San Diego, and a Juris Doctor from Cornell University Law School. |
J. Daniel Cole |
Mr. J. Daniel Cole is Independent Director of Thoratec Corporation. Since March 1997, Mr. Cole has been a general partner of the Spray Venture Fund of Boston. Mr. Cole has also been a venture partner at Oxford Bioscience Partners since 2009. Mr. Cole was President and Chief Operating Officer of SciMed Life Systems Corporation, an interventional cardiology products company, from March 1993 to March 1995, and Senior Vice President and Group President of the vascular business of Boston Scientific Corporation, a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties, from March 1995 to March 1997. He has also held a number of senior executive positions at Baxter Healthcare Corporation from April 1982 to January 1993, including President of its Edwards Less Invasive Surgery Division and its Critical Care Division. Mr. Cole also serves as a member of the board of directors of several private companies. |
Steven Collis |
Mr. Steven H. Collis is Independent Director of Thoratec Corp. Mr. Collis is currently President and Chief Operating Officer of AmerisourceBergen Corporation, and President of its AmerisourceBergen Drug Company (ABDC). Mr. Collis has been named to succeed the current chief executive officer of AmerisourceBergen Corporation effective July 1, 2011. AmerisourceBergen Corporation is a pharmaceutical services company. Mr. Collis joined Bergen Brunswig Corporation, a predecessor to AmerisourceBergen, in 1994 as general manager of Alternate Site Distributors, and was named President of its Specialty Group in 1999. He was previously a principal and general manager of Sterling Medical, a national provider and distributor of medical disposable supplies, health management services and continuous quality management programs to the home care market. |
Elisha Finney |
Ms. Elisha W. Finney is no longer Independent Director of Thoratec Corporation, effective May 22, 2013. Ms. Finney is Senior Vice President and Chief Financial Officer of Varian Medical Systems, a manufacturer of medical devices and software for treating cancer. Ms. Finney joined Varian Medical in 1988 as a risk manager and was named corporate treasurer in 1998. She was named Vice President, Finance and Chief Financial Officer in 1999, and promoted to Senior Vice President in 2005. Before that, she held risk management positions with the Fox Group and Beatrice Foods. Ms. Finney served as a member of the board of directors of Laserscope Inc. from August 2005 until its acquisition by American Medical Systems in July 2006. |
D. Keith Grossman |
Mr. D. Keith Grossman is Independent Director of Thoratec Corporation. Since December 2011, Mr. Grossman has been the President and Chief Executive Officer and a director of Conceptus, Inc, a women's health medical device company. From September 2007 to December 2011, Mr. Grossman served as a Managing Director with TPG (Texas Pacific Group), a private equity firm, in their healthcare investment team. From January 1996 until January 2006, Mr. Grossman served as President and Chief Executive Officer. Prior to joining , Mr. Grossman was a Division President of Major Pharmaceuticals, Inc., a pharmaceutical distributor, from June 1992 to September 1995, at which time it was sold. From July 1988 to June 1992, Mr. Grossman served as the Vice President of Sales and Marketing for Calcitek, Inc., a manufacturer of implantable medical devices and a division of Sulzermedica (formerly Intermedics, Inc.). Prior to 1988, Mr. Grossman held various other sales and marketing management positions within the McGaw Laboratories Division of American Hospital Supply Corporation. Mr. Grossman has served as a member of the board of directors of Intuitive Surgical, Inc. and Kyphon, Inc. |
William Hawkins |
Mr. William A. Hawkins, III, is Independent Director of Thoratec Corp. Mr. Hawkins currently serves as President and Chief Executive Officer of Immucor, Inc. and as a Senior Advisor to TPG Capital. Previously, he held a number of senior executive positions at Medtronic, Inc., including the role of Chairman and Chief Executive Officer. Prior to Medtronic, Hawkins was the Chief Executive Officer of Novoste Corporation and held leadership positions at American Home Products, Eli Lilly, Johnson & Johnson, and Guidant. Additionally, he has served on a number of corporate and non-profit boards of directors. |
Paul LaViolette |
Mr. Paul A. LaViolette is Independent Director of Thoratec Corporation. Since January 2011, Mr. LaViolette has been a partner with SV Life Sciences, a venture capital adviser and manager in the life sciences sector, where he was a venture partner from December 2008 until December 2010. Mr. LaViolette was Chief Operating Officer of Boston Scientific Corporation, a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties, from 2004 until 2008 and joined Boston Scientific in January 1994. Prior to becoming its Chief Operating Officer, Mr. LaViolette held positions with Boston Scientific as Senior Vice President and Group President, Cardiovascular for Boston Scientific's Scimed, EPT and Target businesses, President of Scimed, Senior Vice President and Group President-Nonvascular Businesses, and President, Boston Scientific International, and Vice President-International. Prior to joining Boston Scientific, he was employed by C.R. Bard, Inc. in various capacities, including President, U.S.C.I. Division, President, U.S.C.I. Angioplasty Division, Vice President and General Manager, U.S.C.I. Angioplasty Division, and Vice President U.S.C.I. Division. Mr. LaViolette serves as a member of the board of directors of Conceptus, Inc. and TranS1, Inc., as well as a member of the board of directors of several private medical technology companies. |
Daniel Mulvena |
Mr. Daniel M. Mulvena is Independent Director of Thoratec Corporation. Mr. Mulvena is the founder and owner of Commodore Associates, a consulting company. Mr. Mulvena was Group Vice President Cardiac/Cardiology and a member of the operating committee for Boston Scientific, a medical device company, from February 1992 to May 1995. Prior to that, he was the President and Chief Executive Officer and Chairman of Lithox Systems, Inc., an early stage medical device company. Prior to that, Mr. Mulvena held a number of executive positions, including President of the Implants Division and President of the Cardiosurgery Division, at C.R. Bard, Inc. From 1997 until February 2011, Mr. Mulvena also served as a member of the board of directors of Zoll Medical Corporation. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Neil Dimick |
-- |
Gerhard Burbach |
5,118,820 |
Taylor Harris |
850,039 |
David Lehman |
1,404,830 |
J. Daniel Cole |
-- |
Steven Collis |
-- |
Elisha Finney |
-- |
D. Keith Grossman |
1,404,050 |
William Hawkins |
-- |
Paul LaViolette |
-- |
Daniel Mulvena |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Neil Dimick |
0 | 0 |
Gerhard Burbach |
50,000 | 1,040,910 |
Taylor Harris |
0 | 0 |
David Lehman |
28,775 | 632,452 |
J. Daniel Cole |
0 | 0 |
Steven Collis |
0 | 0 |
Elisha Finney |
0 | 0 |
D. Keith Grossman |
716,000 | 4,178,550 |
William Hawkins |
0 | 0 |
Paul LaViolette |
0 | 0 |
Daniel Mulvena |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
FINNEY ELISHA W |
625 | $33.95 |
DIMICK NEIL F |
1,250 | $33.93 |
HARRIS TAYLOR C |
924 | $35.71 |
LEHMAN DAVID AARON |
1,574 | $35.79 |
BURBACH GERHARD F |
7,406 | $35.79 |
HARRIS TAYLOR C |
561 | $35.79 |
LEHMAN DAVID AARON |
11,448 | $0.00 |
HARRIS TAYLOR C |
11,448 | $0.00 |
BURBACH GERHARD F |
47,038 | $0.00 |
BURBACH GERHARD F |
6,613 | $35.28 |
LEHMAN DAVID AARON |
1,531 | $35.28 |
LEHMAN DAVID AARON |
1,539 | $35.29 |
BURBACH GERHARD F |
7,828 | $35.29 |
HARRIS TAYLOR C |
735 | $35.29 |
LEHMAN DAVID AARON |
1,283 | $35.57 |
BURBACH GERHARD F |
4,422 | $35.57 |
LEHMAN DAVID AARON |
13,125 | $20.34 |
LEHMAN DAVID AARON |
13,125 | $38.06 |
LEHMAN DAVID AARON |
4,375 | $20.34 |
LEHMAN DAVID AARON |
8,775 | $37.41 |
LEHMAN DAVID AARON |
4,400 | $17.91 |
COLLIS STEVEN H |
3,000 | $0.00 |
GROSSMAN D KEITH |
10,000 | $37.62 |
MULVENA DANIEL M |
2,500 | $37.64 |
COLE JAMES DANIEL |
4,000 | $37.92 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
